19 citations
,
March 1994 in “Fertility and sterility” This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.
18 citations
,
August 2019 in “Clinical breast cancer” This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.
March 2023 in “JAAD case reports” This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.
74 citations
,
December 1995 in “The Journal of Clinical Endocrinology & Metabolism” This study found that treatment with leuprolide plus cyclic estrogen/progestin may lead to a faster and greater improvement in hirsutism compared to a standard oral contraceptive regimen.
7 citations
,
October 1974 in “PubMed” In this study, topical estrogens and corticosteroids were associated with decreased telogen rates in 52% of androgenetic alopecia patients, suggesting potential clinical improvement, though the role of corticosteroids remains unclear.